Influenza and other respiratory viruses · 2026
Influenza Vaccine Effectiveness Against Mild and Severe Outcomes: A Comparison Study in Portugal.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mourao Francisco, Gómez Verónica, Soares Patrícia, Rodrigues Ana Paula, Dias Carlos Matias, Machado Ausenda
Аннотация
BACKGROUND: Influenza vaccination is an effective public health intervention to lessen influenza effect on healthcare and has been recommended to prevent severe outcomes. Previous studies present higher influenza vaccine effectiveness (IVE) estimates against primary care medically attended (outpatients) compared to hospitalised cases (inpatients). Inconsistencies in study designs may hinder comparisons of IVE in preventing mild (outpatient consultations) versus severe influenza (inpatient admissions). We aimed to compare IVE against mild and severe influenza within primary care and hospital networks in Portugal from 2015/16 to 2023/24.
METHODS: Using the test-negative design, we analysed 3393 RT-PCR-tested patients with influenza-like illness in outpatients or severe acute respiratory infection in inpatients. IVE was estimated using a generalised linear mixed model with fixed effects for sex, age category, comorbidities, month of symptom onset and random effects for season. For difference estimation, 95% confidence intervals (CI) were obtained through bootstrapping.
RESULTS: IVE was 40.4% (22.7; 54.0) for outpatients and 38.7% (17.6; 54.5) for inpatients. The 1.7% difference was not statistically significant (-22.0; 26.8). Subgroup analyses for individuals aged ≥ 65 years, patients with comorbidities and by influenza A subtype showed similar non-significant differences, ranging from -1% to 17%.
CONCLUSION: We found no statistically significant difference in IVE against mild or severe influenza infection. However, comparison across care settings should be interpreted cautiously, as patients differ in sociodemographic characteristics and comorbidity burden. Although limited sample size may reduce statistical power, the small magnitude of observed differences suggests that patients benefit from current vaccination strategies across care settings.
METHODS: Using the test-negative design, we analysed 3393 RT-PCR-tested patients with influenza-like illness in outpatients or severe acute respiratory infection in inpatients. IVE was estimated using a generalised linear mixed model with fixed effects for sex, age category, comorbidities, month of symptom onset and random effects for season. For difference estimation, 95% confidence intervals (CI) were obtained through bootstrapping.
RESULTS: IVE was 40.4% (22.7; 54.0) for outpatients and 38.7% (17.6; 54.5) for inpatients. The 1.7% difference was not statistically significant (-22.0; 26.8). Subgroup analyses for individuals aged ≥ 65 years, patients with comorbidities and by influenza A subtype showed similar non-significant differences, ranging from -1% to 17%.
CONCLUSION: We found no statistically significant difference in IVE against mild or severe influenza infection. However, comparison across care settings should be interpreted cautiously, as patients differ in sociodemographic characteristics and comorbidity burden. Although limited sample size may reduce statistical power, the small magnitude of observed differences suggests that patients benefit from current vaccination strategies across care settings.